These occur when proteins normally found in nerve cells—known as called tau protein—clump together ... Positron emission tomography (PET): This imaging study detects areas of higher or lower ...

four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA executed an Exclusive License and Option Agreement (License) with AbbVie for the ...

TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...

Enigma Biomedical USA Inc. has selected two four-repeat tau (4R tau) protein PET imaging biomarkers to advance into phase I studies. These imaging biomarkers show promise as important new tools in ...

Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech's financial resources as it prepares regulatory filings for tau-targeting Alzheimer's drug ...

four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA executed an Exclusive License and Option Agreement (License) with AbbVie for the ...

Exelixis, Inc announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with ...

After hours: March 21 at 4:05:01 PM EDT Loading Chart for DRTS ...